232 related articles for article (PubMed ID: 31843957)
1. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice.
Pouwer MG; Pieterman EJ; Worms N; Keijzer N; Jukema JW; Gromada J; Gusarova V; Princen HMG
J Lipid Res; 2020 Mar; 61(3):365-375. PubMed ID: 31843957
[TBL] [Abstract][Full Text] [Related]
2. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
Kühnast S; van der Hoorn JW; Pieterman EJ; van den Hoek AM; Sasiela WJ; Gusarova V; Peyman A; Schäfer HL; Schwahn U; Jukema JW; Princen HM
J Lipid Res; 2014 Oct; 55(10):2103-12. PubMed ID: 25139399
[TBL] [Abstract][Full Text] [Related]
3. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.
Gao F; Wang ZJ; Ma XT; Shen H; Yang LX; Zhou YJ
Lipids Health Dis; 2021 Sep; 20(1):106. PubMed ID: 34511134
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
[TBL] [Abstract][Full Text] [Related]
5. Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice.
van Gemert Y; Kozijn AE; Pouwer MG; Kruisbergen NNL; van den Bosch MHJ; Blom AB; Pieterman EJ; Weinans H; Stoop R; Princen HMG; van Lent PLEM
Osteoarthritis Cartilage; 2021 Sep; 29(9):1314-1323. PubMed ID: 33722697
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
Chan DC; Watts GF; Somaratne R; Wasserman SM; Scott R; Barrett PHR
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
[TBL] [Abstract][Full Text] [Related]
9. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
[TBL] [Abstract][Full Text] [Related]
10. Effect of evolocumab on the progression and stability of atherosclerotic plaques as evaluated by grayscale and iMAP-IVUS.
Kong Q; Liu M; Li Y; Zhu Q; Su G
Ann Palliat Med; 2020 Sep; 9(5):3078-3088. PubMed ID: 33065780
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
[TBL] [Abstract][Full Text] [Related]
12. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
Bays H; Gaudet D; Weiss R; Ruiz JL; Watts GF; Gouni-Berthold I; Robinson J; Zhao J; Hanotin C; Donahue S
J Clin Endocrinol Metab; 2015 Aug; 100(8):3140-8. PubMed ID: 26030325
[TBL] [Abstract][Full Text] [Related]
13. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice.
van de Poll SW; Delsing DJ; Wouter Jukema J; Princen HM; Havekes LM; Puppels GJ; van der Laarse A
J Mol Cell Cardiol; 2003 Jan; 35(1):109-18. PubMed ID: 12623305
[TBL] [Abstract][Full Text] [Related]
14. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Landlinger C; Pouwer MG; Juno C; van der Hoorn JWA; Pieterman EJ; Jukema JW; Staffler G; Princen HMG; Galabova G
Eur Heart J; 2017 Aug; 38(32):2499-2507. PubMed ID: 28637178
[TBL] [Abstract][Full Text] [Related]
15. Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab.
Sun J; Lepor NE; Cantón G; Contreras L; Hippe DS; Isquith DA; Balu N; Kedan I; Simonini AA; Yuan C; Zhao XQ; Hatsukami TS
Int J Cardiovasc Imaging; 2021 Apr; 37(4):1415-1422. PubMed ID: 33392875
[TBL] [Abstract][Full Text] [Related]
16. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
Robinson JG; Colhoun HM; Bays HE; Jones PH; Du Y; Hanotin C; Donahue S
Clin Cardiol; 2014 Oct; 37(10):597-604. PubMed ID: 25269777
[TBL] [Abstract][Full Text] [Related]
18. Evinacumab in Patients with Refractory Hypercholesterolemia.
Rosenson RS; Burgess LJ; Ebenbichler CF; Baum SJ; Stroes ESG; Ali S; Khilla N; Hamlin R; Pordy R; Dong Y; Son V; Gaudet D
N Engl J Med; 2020 Dec; 383(24):2307-2319. PubMed ID: 33196153
[TBL] [Abstract][Full Text] [Related]
19. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Kühnast S; van der Tuin SJ; van der Hoorn JW; van Klinken JB; Simic B; Pieterman E; Havekes LM; Landmesser U; Lüscher TF; Willems van Dijk K; Rensen PC; Jukema JW; Princen HM
Eur Heart J; 2015 Jan; 36(1):39-48. PubMed ID: 25142968
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
